YS Biopharma Financial Statements From 2010 to 2026
YS Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing YS Biopharma's valuation are provided below:YS Biopharma Co does not at this time have any fundamental measures for analysis.
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Check YS Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among YS Biopharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . YS Biopharma financial statements analysis is a perfect complement when working with YS Biopharma Valuation or Volatility modules.
YS Biopharma |
YS Biopharma Co Company Shares Outstanding Analysis
YS Biopharma's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current YS Biopharma Shares Outstanding | 188.33 M |
Most of YS Biopharma's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, YS Biopharma Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, YS Biopharma Co has 188.33 M of shares currently outstending. This is 4.32% higher than that of the Biotechnology sector and 76.25% higher than that of the Health Care industry. The shares outstanding for all United States stocks is 67.07% higher than that of the company.
YS Biopharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining YS Biopharma's current stock value. Our valuation model uses many indicators to compare YS Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across YS Biopharma competition to find correlations between indicators driving YS Biopharma's intrinsic value. More Info.YS Biopharma Co is rated below average in return on equity category among its peers. It is rated third in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value YS Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Thematic Opportunities
Explore Investment Opportunities
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in YS Biopharma Stock
If you are still planning to invest in YS Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the YS Biopharma's history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |